All In Biotech

Drug Trial Radar · NCT01777269

Prospective Sexual Function Study for BPH Subjects

A Prospective Study of Sexual Function in Sexually Active Men Treated for BPH

Last checked: Nov 20, 2026Latest source record: Aug 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 489 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

489

Actual

Start

Feb 18, 2013

Primary completion

Apr 5, 2016

Study completion Apr 5, 2016

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jan 28, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Male only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an European double-blind, placebo controlled parallel group comparison of DUODART (fixed dose combination of dutasteride 0.5mg and tamsulosin 0.4mg, one capsule daily) and placebo. PRIMARY OBJECTIVE: To assess the change in sexual function from baseline to 1 year in sexually active men with at least moderate BPH who are treated with DUODART, compared to men treated with placebo .

Conditions

  • Prostatic Hyperplasia

Interventions

  • Dutasteride plus tamsulosinDrug

    Take 1 capsule daily

  • PlaceboDrug

    Take one capsule daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes From Baseline (BL) in Total Score From the Full Men's Sexual Health Questionnaire (MSHQ) at 12 MonthsTime frame: Baseline and 12 months

Locations

67 sites in 7 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Randwick, New South Wales, Australia

  • GSK Investigational Site

    Sydney, New South Wales, Australia

  • GSK Investigational Site

    Wahroonga, New South Wales, Australia

  • GSK Investigational Site

    Herston, Queensland, Australia

  • GSK Investigational Site

    Kippa-Ring, Queensland, Australia

  • GSK Investigational Site

    Adelaide, South Australia, Australia

  • GSK Investigational Site

    Heidelberg, Victoria, Australia

  • GSK Investigational Site

    Malvern, Victoria, Australia

  • GSK Investigational Site

    Garches, France

  • GSK Investigational Site

    Nantes, France

  • GSK Investigational Site

    Nîmes, France

  • GSK Investigational Site

    Orléans, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Thouars, France

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Eisleben Lutherstadt, Germany

  • GSK Investigational Site

    Nuremberg, Bavaria, Germany

  • GSK Investigational Site

    Hagenow, Brandenburg, Germany

  • GSK Investigational Site

    Oranienburg, Brandenburg, Germany

  • GSK Investigational Site

    Strausberg, Brandenburg, Germany

  • GSK Investigational Site

    Marburg, Hesse, Germany

  • GSK Investigational Site

    Buchholz, Lower Saxony, Germany

  • GSK Investigational Site

    Aachen, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Dortmund, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Dülmen, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Leipzig, Saxony, Germany

  • GSK Investigational Site

    Hettstedt, Saxony-Anhalt, Germany

  • GSK Investigational Site

    Kiel, Schleswig-Holstein, Germany

  • GSK Investigational Site

    Wedel, Schleswig-Holstein, Germany

  • GSK Investigational Site

    Argos, Greece

  • GSK Investigational Site

    Athens, Greece

  • GSK Investigational Site

    Athens, Greece

  • GSK Investigational Site

    Athens, Greece

  • GSK Investigational Site

    Athens, Greece

  • GSK Investigational Site

    Larissa, Greece

  • GSK Investigational Site

    Budapest, Hungary

  • GSK Investigational Site

    Budapest, Hungary

  • GSK Investigational Site

    Budapest, Hungary

  • GSK Investigational Site

    Debrecen, Hungary

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.